市場調查報告書
商品編碼
927825

HER2陰性乳癌的全球市場:成長,趨勢,預測(2020年∼2025年)

HER-2 Negative Breast Cancer Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

人表皮生長因子受體2(HER-2)陰性乳腺癌是指不含有高水平HER-2蛋白的乳腺癌細胞。過去十年來的主要課題是如何最大程度控制症狀並改善生存率。對於所有類型的乳腺癌,主要缺點之一是儘管乳腺癌的早期治療有所進步,但乳腺癌患者的複發還是很常見。儘管HER-2陽性疫苗在所有地區都廣為人知,但HER-2陰性疫苗的存在也在穩步確立,並且在這一方向上的臨床和研發活動將在預測期內正向推動市場順利成長。然而,高昂的治療費用和替代治療方法的使用有可能限制該市場的增長。

本報告提供全球HER2陰性乳癌市場調查,提供市場概要,各不同治療·各地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 乳癌患者負擔的增加
    • 不同乳癌治療醫學的進步
  • 阻礙市場要素
    • 治療費高
    • HER-2陰性乳癌相關意識低
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場細分化

  • 不同治療
    • 化療
    • 放射線
    • 荷爾蒙療法
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca PLC
    • Celgene Corporation (Bristol Myers Squibb Company)
    • Eli Lilly and Company
    • GlasxoSmithKline
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer

第7章 市場機會及未來趨勢

目錄
Product Code: 68178

The human epidermal growth factor receptor 2 (HER-2) negative breast cancer refers to the cancerous cells in the breast which do not contain high levels of protein HER-2. The major requirement in the present decade is to improve upon the maximising the symptom control and extending survival. In all types of breast cancers, one of the major drawback is that despite the advancements in the treatment of early stage of breast cancers, the recurrence of the disease among the patients is quite common. While, HER-2 positive is highly prevalent across all geographies, the presence of HER-2 negative is also steadily growing and clinical advancement as well as research development activities in this direction is expected to grow better over the forecast period. The high cost of treatment and availability of alternative treatments are expected to restrict the growth of this market.

Key Market Trends

Treatment via Hormonal therapy is Expected to be the Major Contributor to the Market

  • There are several drugs approved in the market which can block the hormones or lower their levels in the body, which helps in treatment of HER-2 negative breast cancer. Some of the well-established drugs include tamoxifen, fulvestrant, goserelin, olaparib, and others.
  • Some of the companies advancing their drugs development and R&D activities in this sub-segment of the market include AstraZeneca, Biomarin, Abbvie, Merck and Co. Inc., and Tesaro, with their products in the late the stage of clinical development.
  • One of the challenges among the manufacturers is the occurrence of resistance is common problem in hormonal therapy. Therefore, combination therapy with hormonal therapy to prevent or overcome the hormone resistance is highly considered and are into development.

North America is Expected to Hold a Significant Share in the Market with Similar Trend in the Forecast Period

North America expected to hold a major market share in the global HER-2 negative breast cancer market owing to better healthcare infrastructure, and growing number of foundations and independent venture groups supporting the biopharmaceutical manufacturers. The presence of major manufacturers across the different states, getting funding from different venture partners drives the market related to HER-2 negative breast cancer. As per the American cancer Society, 2017-2018, the negative HER-2 cancers are twice as common in the black women as compared to white women in the United States, also more common in the in pre-menopausal women and those with a BRCA1 gene mutation. The challenges associated within such population is early diagnosis and right treatment procedure to the identified set of patient population with the HER-2 negative breast cancers. The availability of good government support along with better disposable income option among all populations as well as good percentage of medical tourism across the North America region, fuels the market growth.

Competitive Landscape

The major focus among the companies is to develop combination therapies which shall overcome the resistance of existing drug therapies in the market thus boosting the targeted disease treatment. This is done via collaboration, and partnerships among the market players. Some of the major companies in this segment include AstraZeneca, Eli Lilly and Company, Novartis AG, Pfizer, GSK, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Breast Cancers
    • 4.2.2 Medical Advancements by Breast Cancers Treatment
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Less Awareness Regarding HER-2 Negative Breast Cancer
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Treatment
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiation
    • 5.1.3 Hormonal Therapy
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Celgene Corporation (Bristol Myers Squibb Company)
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 GlasxoSmithKline
    • 6.1.5 Merck & Co., Inc.
    • 6.1.6 Novartis AG
    • 6.1.7 Pfizer

7 MARKET OPPORTUNITIES AND FUTURE TRENDS